Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
224
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Alumis Inc. market cap is $626.47M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Alumis Inc. 52 week high is $31.35 as of November 19, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Alumis Inc. 52 week low is $4.35 as of November 19, 2026.
Alumis Inc. stock price today is $4.40.
Alumis Inc. stock price yesterday was $4.84.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Alumis Inc.'s P/E ratio is -1.26.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Alumis Inc. P/B ratio is 1.5061.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Alumis Inc. 50-day moving average is $6.90.